Altimmune Announces Poster Presentation of HepTcell Program at 2017 Keystone Symposia Conference
Gaithersburg, Maryland – October 26, 2016 – Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that a poster detailing the design and preclinical evaluation of its HepTcell immunotherapeuticfor the treatment of chronic hepatitis B infection will be presented at the 2017 Keystone Symposia Conference taking place October 25 – 29, 2016 in London.
The poster, entitled, “Design and pre-clinical evaluation of HepTcellTM: a therapeutic vaccine to treat chronic hepatitis B,” will be presented by Katie Anderson, PhD, at the Translational Vaccinology for Global Health session on Thursday, October 27, 2016 from 7 – 10 PM GMT.
Bertand Georges PhD, Chief Technology Officer of Altimmune, stated, “The preclinical results to be presented demonstrate HepTcell’s ability to stimulate CD4+ and CD8+ T cell responses irrespective of HBV genotype or patient ethnicity, and break immune tolerance to hepatitis B virus (HBV) chronic infection. Our Phase I trial continues to progress, and we are extremely excited about the potential for HepTcell to serve as a first-in-class functional cure for chronic Hepatitis B patients.”
Altimmune is a clinical stage immunotherapeutic company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines. Using these technologies, Altimmune has developed three novel clinical stage product candidates that potentially represent an entirely new approach to harnessing the immune system. The Company’s most advanced product candidate, NasoVAX, is a Phase 2-ready intranasally-delivered recombinant influenza vaccine offering broad and rapid protection with potential for significant advantages over traditional flu vaccines. The second most advanced product candidate, HepTcell, is being tested as an immunotherapy for patients chronically infected with hepatitis B and has the potential to provide a functional cure. With the support of the U.S. Biomedical Advanced Research and Development Authority, or BARDA, the Company is developing a third product candidate, NasoShield, a first-in-class anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. The Company intends to leverage the RespirVec and Densigen platforms to develop additional product candidates for a variety of indications.